Trimetrexate, a highly lipid-soluble quinazoline antifolate now undergoing trials as an anticancer agent, was found to be a potent inhibitor of the dihydrofolate reductase (DHFR) isolated from Toxoplasma gondii. The concentration required for 50% inhibition of protozoal DHFR was 1.4 nM. As an inhibitor of this enzyme, trimetrexate was almost 600-fold (amount of antifolate required to inhibit catalytic reaction by 50%) and 750-fold (inhibition constant) more potent than pyrimethamine, the DHFR inhibitor currently used to treat toxoplasma infection. When the protozoan was incubated with 1 jiM trimetrexate, the drug rapidly reached high intracellular concentrations. Since toxoplasma organisms lack a transmembrane transport system for physiologic folates, host toxicity can be prevented by co-administration of the reduced folate, leucovorin, without reversing the antiprotozoal effect. The effectiveness of trimetrexate against toxoplasma was demonstrated both in vitro and in vivo. Proliferation of toxoplasma in murine macrophages in vitro was completely inhibited by exposure of these cells to i0' M trimetrexate for 18 h. When used alone, trimetrexate was able to extend the survival of T. gondii-infected mice.
Introduction
Dihydrofolate reductase (DHFR)' (E.C. 1.5.1.3; 5,6,7,8-tetrahydrofolate:NADP+ oxidoreductase) is required to maintain the intracellular pool of reduced folates in rapidly dividing cells. Inhibitors ofthis enzyme have proved effective in both antineoplastic and antimicrobial chemotherapy. Methotrexate potently inhibits DHFR from mammalian and bacterial sources (inhibition constant [Ki] , 10-" M) but requires transport by a folatespecific membrane carrier found in mammalian cells, and is therefore primarily useful as an antineoplastic agent (1) . The diaminopyrimidines pyrimethamine and trimethoprim have very different properties compared with methotrexate in that they have only intermediate inhibitory activity against bacterial DHFR (K, = 1 X 10-8 M) and even less potency against mammalian DHFR (2) . Despite this reduced potency, these drugs have a major advantage over methotrexate as they readily penetrate both mammalian and bacterial cells and thus are used primarily as antibacterial agents in combination with an inhibitor of folate synthesis, such as sulfadiazine or sulfamethoxazole.
Receivedfor publication 3 March 1986 and in revisedform 12 The diaminopyrimidines, in combination with sulfonamides, have become the primary form of therapy for certain protozoal infections including toxoplasmosis (3), although little is known concerning their transport into toxoplasma trophozoites and the potency of their inhibition of protozoal DHFR.
Toxoplasma gondii infection occurs in 30-50% of North Americans, but severe or life-threatening disease occurs almost exclusively in patients with defective cell-mediated immunity who appear to reactivate previously acquired infection (3) . Re- cently toxoplasmosis has been recognized as an unusually prevalent opportunistic infection in patients with acquired immunodeficiency syndrome (AIDS) (4) .
The rapidly increasing incidence oftoxoplasma encephalitis in AIDS patients has highlighted the need for more effective therapies and for alternative drugs for the considerable number of patients (up to 60%) who develop allergic reactions or serious side effects during therapy with a sulfonamide and trimethoprim or pyrimethamine (5) . No alternative regimen to sulfonamide and pyrimethamine has been found effective for the therapy of toxoplasma encephalitis. In the current study, we have found that trimetrexate (2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline), a lipid-soluble antifolate now under clinical evaluation as an anticancer drug, can be used with leucovorin as a potent and selective antiprotozoal drug with no apparent toxicity for either the mammalian host or infected cells.
Methods
T. gondii was isolated from the peritoneal exudate of BALB/c mice 3 d after intraperitoneal inoculation of T. gondii trophozoites (RH strain). The exudate was suspended in phosphate-buffered saline and the toxoplasma trophozoites were separated from inflammatory cells by differential centrifugation as previously described (6) . The sedimented toxoplasma organisms were then resuspended in I ml of phosphate-buffereA saline containing 50 ,g/ml of each of the protease inhibitors chymostatin and leupeptin (7) . The organisms were disrupted with a 60-s burst from a cell disrupter (Virsonic model (11) .
The transport of leucovorin, methotrexate, and trimetrexate was investigated using published techniques (12, 13) .
[3H]-1-5-Formyl-H4PteGlu (leucovorin) was synthesized from [3',5',7,9-3H]folic acid by enzymatic reduction to tetrahydrofolic acid followed by formylation and purification (14) . [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] ['4C ]trimetrexate (13.1 mCi/mmol, sp act) for specific time periods followed by centrifugation at 15,000 g for 1 min through 1 ml ofF50 silicon fluid (General Electric Co., Silicone Products Div., Waterford, NY) to separate the cells from the radiolabeled media. The cell pellets were disrupted by dissolution in 0.5 ml of I M NaOH; the extract was dissolved in 10 ml of scintillant and radioactivity counted in a liquid scintillation counter. Nonspecific background counts were established for each radiolabeled compound by adding the radiolabeled compound to the cells and then immediately quenching the transport of the radiolabeled compound by the addition of a 1000-fold excess of unlabeled compound followed by processing as outlined above.
The peritoneal macrophage model (6) was used to illustrate the ability of the antifolates to inhibit toxoplasma replication in the intact cell. Peritoneal macrophages harvested from BALB/c mice were plated on Lab-Tek slides at a concentration of 106/ml RPMI-1640 with 10% fetal calf serum (FCS) at 37°C. After 24 h, the medium was removed and 1 ml of toxoplasma at a concentration of 2 X 106/ml RPMI-1640 with 10% FCS was added to the slides; after 30 min the supernate was removed, the slides were washed vigorously, and 1 ml RPMI-1640 and 10% FCS plus drug were added. I and 18 h later the slides were stained with Diffquick (Dade Diagnostics, Aguada, PR). 200 to 400 cells were counted and the mean number of toxoplasma per vacuole was calculated. Each experiment was performed in duplicate.
In vivo animal studies were conducted using female BALB/c mice weighing -20 g. Groups consisted of 8 to 10 animals and toxoplasmainfected animals were inoculated intraperitoneally with 50,000 T. gondii (RH strain) harvested from 3-or 4-d peritoneal exudates. All animals were given food and water ad lib. All intraperitoneal drugs were given via a 25-gauge needle, and all oral drugs were given in the drinking water. Pyrimethamine could not be solubilized for intraperitoneal injection, and a dose of 180 mg/kg per d represents its maximal solubility in the drinking water.
Results
To investigate the antimetabolic effects of antifolates, we examined the ability of various antifolates to inhibit DHFR from a human source, from T. gondii, and from a bacterial source (L. casei). For each inhibitor, the ability to inhibit the catalytic reaction was determined (Table I) . Because some DHFR inhibitors such as methotrexate may be "slow" binding to DHFR as compared with the more rapid binding of the diaminopyrimi- 
Discussion
This report documents the antiprotozoal activity of trimetrexate, a lipid-soluble antifolate that is 600-fold (150) and 750-fold (K,) more potent than the conventionally used antifolate, pyrimethamine, as an inhibitor of the protozoal DHFR. In comparative studies of inhibitors of DHFR using enzyme derived from mammalian, protozoan, and bacterial sources, the diaminopyrimidine antifolates (trimethoprim and pyrimethamine) only weakly inhibited the protozoal and mammalian enzymes, in contrast to the pteridine and quinazoline structures, which potently inhibited the enzyme from all three sources. Bacteria possess a DHFR exquisitely sensitive to the diaminopyrimidines due to the availability of additional hydrogen bonding at valine 1 5 as compared with the lack of bonding at this position in the insensitive mammalian enzyme (17) . The The latter compound, a physiologic reduced folate (5-formyltetrahydrofolate), is taken up by host tissues and prevents the toxicity ofDHFR inhibitors for bone marrow and gastrointestinal epithelium. In vitro and in vivo experiments confirm that the antiprotozoal effect of trimetrexate is preserved in the presence of leucovorin and that host toxicity of otherwise lethal doses of the drug may be averted. In the in vivo studies, trimetrexate alone was able to prolong the median survival of toxoplasmainfected mice, while pyrimethamine alone, at maximal concentrations soluble in drinking water, was found to be only minimally effective. Since the doses of trimetrexate used in this study were sublethal to allow direct comparison to equivalent pyrimethamine doses, leucovorin was not required for host protection. However, leucovorin was included in the intraperitoneal experiments to show its inability to obviate the antitoxoplasma effects oftrimetrexate. Further in vivo experiments are presently being conducted to compare the efficacy of trimetrexate-leucovorin to other regimens, and these will be reported in a subsequent publication. It is likely that the addition of a sulfa to the trimetrexate-leucovorin regimen would enhance the effectiveness of this combination by inhibiting the de novo synthesis of folates in the parasite (18).
These studies suggest that lipid-soluble antifolates deserve additional scrutiny in the development of more effective and less toxic antiprotozoal therapy. Clinical trials using the combination of trimetrexate-leucovorin for the treatment of refractory toxoplasma encephalitis in the AIDS population are currently being conducted. Preliminary results suggest that the combination is an effective therapeutic option.
